Report title: Commercial Insight: Migraine - Opportunities will exist in the wake of generic attack
from Datamonitor Premium Research Reports
187 page (57580 word) report published Sep 26, 2007

Price $15,200.00 available for immediate download
Report Overview
 
Search Inside
 
About Datamonitor Premium Research R...

...With the seven triptan brands continuing to dominate acute migraine treatment and Ortho- McNeil s Topamax (topiramate) driving sales in the prophylactic market, seven major market revenues increased by 8.1% from 2005 to $3.7 billion in 2006. The launch of pipeline drugs will only periodically offset genericization of GSK s Imitrex (sumatriptan) and Topamax. Further triptan genericization will dictate market dynamics through to 2016. Nevertheless, the largely under served prophylactic market and additional indications such as menstrual migraine will conti nue to present attractive opportunities to both current and future market players. Coverage: Seven major markets (US, Franc e, Germany, Italy, Spain, UK, and Japan) ...

Report Type: Report
Industry(ies): Diversified Services
Free Sample: Click Here to Download
Format:
PDF Adobe Acrobat


Enter the keyword(s) which you would like to search for within this document and click "Search"  


Price: $15,200.00



  Can't Decide?

Purchasing premium research sight unseen can be intimidating. At Alacra we want you to know what you are getting. Visit our FAQ or ask our Customer Service Team any questions about the report you are considering purchasing.